Currently submitted to: JMIR Preprints
Date Submitted: Jun 8, 2023
Open Peer Review Period: Jun 8, 2023 - May 23, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Adrenaline Intolerance in ASD Curing From Autoimmune Pathogens — Sebaceous Immunobiology in Autoimmune Pathogen Research
ABSTRACT
The review is summarative to the clinical trials numbered NCT05711810 and NCT05839236 on ClinicalTrials.gov, with the sole participant's recovery from autoimmune pathogens who was also diagnosed as neurodivergent during the first interventional trial. The review seeks to bridge the literature gaps between psychiatry and the medical sciences on neurodiversity with the focus on immunobiology. It chooses the concept of adrenaline intolerance during the final phase of the recovery process to summarize the clinical evidences. The first part of the review synthesizes the key locations of autism spectrum disorder (ASD)'s neurological differences to neurotypical individuals. With the anatomic overview, the second part reviews the relevances to the immune system and implications in immune reflex. The third part reviews the neuroatypical hormonic paths based on the ASD participant's data, whereby the final recovery process with hypolipidemic agent intervention posed a contradiction between the neuronal needs and autoimmune needs of the participant's internal conditions. The review predicts that the contradiction offers a new window into the study of sebaceous immunobiology.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.